H1 2023 Financial Highlights

Building high-value, sustainable pipeline Phase I IPN 60210 R/R multiple myeloma & R/R DLBCL IPN 60260 Viral cholestatic disease Phase II TAZVERIK (various combinations) R/R malignancies TAZVERIK (+ hormonotherapy) mCRPC FIDRISERTIB FOP Phase III CABOMETYX + ATEZOLIZUMAB 2L mCRPC TAZVERIK + R2 2L FL ELAFIBRANOR 2L PBC Registration ONIVYDE + 5-FU/LV + OXALIPLATIN 1L PDAC BYLVAY Alagille syndrome PALOVAROTENE FOP Oncology Rare Disease Neuroscience ELAFIBRANOR PSC IPN 60250 PSC IP N 10200 Longer-acting neurotoxin Ax IPN 10200 Longer-acting neurotoxin Tx BYLVAY Biliary atresia Information shown as at end of June 2023. R/R: relapsed/refractory; DLBCL: diffuse large B-cell lymphoma; mCRPC: metastatic castration-resistant prostate cancer; FOP: fibrodysplasia ossificans progressiva; PSC: primary sclerosing cholangitis; Ax: aesthetics; Tx: therapeutics; 2L: second line; 1L: first line; R2: lenalidomide + rituximab; FL: follicular lymphoma; PBC: primary biliary cholangitis; PDAC: pancreatic ductal adenocarcinoma. IPSEN Innovation for patient care 11

View entire presentation